As anticipated, anti‐PD‐1 therapy failed to inhibit tumor growth, while anti‐VEGFR2 therapy effectively restored the sensitivity to the anti‐PD‐1 therapy in this model (Figure 9e,f). This evidence concerns the gene KDR and neoplasm.